<DOC>
	<DOC>NCT01367600</DOC>
	<brief_summary>This study is an open-label extension allowing patients who have completed Protocol MNTX 301 to continue to receive SC MNTX.</brief_summary>
	<brief_title>Open-Label Treatment Extension of Protocol MNTX 301</brief_title>
	<detailed_description />
	<mesh_term>Methylnaltrexone</mesh_term>
	<criteria>1. Completion of protocol MNTX 301; DoubleBlind Treatment and OpenLabel Treatment 2. Negative pregnancy test 1. Women who are pregnant and/or nursing 2. Any concurrent experimental drug therapy 3. Evidence of fecal impaction 4. Clinically significant active diverticular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Advanced medical illness</keyword>
</DOC>